nach oben

Zeitschrift für Rheumatologie

Erschienen in:

01.11.2014 | Originalien

Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren’s syndrome

Meta-analysis of possible associations

verfasst von: Y.H. Lee, MD, PhD, J.-H. Kim, G.G. Song

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to determine whether the functional chemokine receptor 5 delta32 (CCR5-Δ32) polymorphism is associated with susceptibility to systemic lupus erythematosus (SLE), vasculitis, and primary Sjogren’s syndrome (pSS).

Results

A total of 12 studies were analyzed, including 5 on SLE, 5 on vasculitis, and 2 on pSS, encompassing 1881 patients and 2391 controls. Meta-analysis indicated no association between SLE and the CCR5-Δ32 allele (OR 0.842, 95 % CI 0.793–1.804, p = 0.657), and no association between the CCR5-Δ32 allele and SLE in Europeans (OR 0.647, 95 % CI 0.306–1.368, p = 0.255). Meta-analysis of the CCR5-Δ32 allele and the Δ32Δ32 + Δ32 W genotype showed no association with lupus nephritis (LN; OR 1.771, 95 % CI 0.475–6.595, p = 0.395; OR 2.192, 95 % CI 0.182–26.42, p = 0.537, respectively). In addition, meta-analysis revealed no association between the CCR5-Δ32 allele and vasculitis in all study subjects and in Europeans (OR 1.241, 95 % CI 0.951–1.620, p = 0.111; OR 1.359, 95 % CI 0.803–2.303, p = 0.254, respectively). However, the overall OR for the CCR5-Δ32 allele was significantly higher in Kawasaki disease (KD; OR 1.746, 95 % CI 1.003–2.955, p = 0.038) and the meta-analysis of the Δ32Δ32 + Δ32 W genotype showed a trend indicating an association with KD (OR 1.683, 95 % CI 0.921–3.077, p = 0.091). No association was found between the CCR5-Δ32 polymorphism and pSS.

Conclusion

This meta-analysis demonstrates that the CCR5-Δ32 polymorphism is associated with KD, but does not facilitate susceptibility to SLE, LN, or pSS.

Lee YH, Nath SK (2005) Systemic lupus erythematosus susceptibility loci defined by genome scan meta-analysis. Hum Genet 118:434–443PubMedCrossRef

Kang SH, Chung BH, Choi SR et al (2011) Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med 26:60–67PubMedCentralPubMedCrossRef

Fox RI (2005) Sjogren’s syndrome. Lancet 366:321–331PubMedCrossRef

Lee YH, Song GG (2012) Associations between eNOS polymorphisms and susceptibility to Behcet’s disease: a meta-analysis. J Eur Acad Dermatol Venereol 26:1266–1271PubMedCrossRef

Szekanecz Z, Kim J, Koch AE (2003) Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 15:15–21PubMedCrossRef

Wu L, LaRosa G, Kassam N et al (1997) Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186:1373–1381PubMedCentralPubMedCrossRef

Liu R, Paxton WA, Choe S et al (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367–377PubMedCrossRef

Benkirane M, Jin DY, Chun RF et al (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 272:30603–30606PubMedCrossRef

Carvalho C, Calvisi SL, Leal B et al (2013) CCR5-Delta32: implications in SLE development. Int J Immunogenet

10.

Schauren JS, Marasca JA, Veit TD et al (2013) CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population. Lupus 22:802–809PubMedCrossRef

11.

Aguilar F, Nunez-Roldan A, Torres B et al (2003) Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J Rheumatol 30:1770–1774PubMed

12.

Maier-Moore JS, Canas CA, Tobon G et al (2013) The CCR5 delta 32 polymorphism (rs333) is not associated with Sjogren’s syndrome or Type 1 Diabetes in Colombians. Clin Immunol 148:206–208PubMedCrossRef

13.

Petrek M, Cermakova Z, Hutyrova B et al (2002) CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol 20:701–703PubMed

14.

Chaudhuri K, Singh Ahluwalia T, Singh S et al (2011) Polymorphism in the promoter of the CCL5 gene (CCL5G-403A) in a cohort of North Indian children with Kawasaki disease. A preliminary study. Clin Exp Rheumatol 29(Suppl 64):S126–S130PubMed

15.

Carmona FD, Rodriguez-Rodriguez L, Castaneda S et al (2011) Role of the CCR5/Delta32CCR5 polymorphism in biopsy-proven giant cell arteritis. Hum Immunol 72:458–461PubMedCrossRef

16.

Breunis WB, Biezeveld MH, Geissler J et al (2007) Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol 150:83–90PubMedCentralPubMedCrossRef

17.

Zhou Y, Huang D, Farver C, Hoffman GS (2003) Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis. J Rheumatol 30:1541–1547PubMed

18.

Pazzola G, Boiardi L, Casali B et al (2013) CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. Mod Rheumatol 23:851–855PubMedCrossRef

19.

Yang SG, Ye DQ, Li XP et al (2003) The SNPs of chemokine RANTES promoter and the mutation of its’ receptor CCR5 in SLE and controls in Han indigenous in Chinese. Chin J Microbiol Immunol 23:723–727

20.

Lee YH, Witte T, Momot T et al (2005) The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52:3966–3974PubMedCrossRef

21.

Nath SK, Harley JB, Lee YH (2005) Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 118:225–234PubMedCrossRef

22.

Lee YH, Harley JB, Nath SK (2006) Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 14:364–371PubMedCrossRef

23.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94PubMedCrossRef

24.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCentralPubMedCrossRef

25.

Davey Smith G, Egger M (1997) Meta-analyses of randomised controlled trials. Lancet 350:1182

26.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

27.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

28.

Mamtani M, Rovin B, Brey R et al (2008) CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus. Ann Rheum Dis 67:1076–1083PubMedCentralPubMedCrossRef

29.

Jhang WK, Kang MJ, Jin HS et al (2009) The CCR5 (-2135C/T) polymorphism may be associated with the development of Kawasaki disease in Korean children. J Clin Immunol 29:22–28PubMedCrossRef

30.

Bidyalaxmi Devi L, Bhatnagar A, Wanchu A, Sharma A (2013) A study on the association of autoantibodies, chemokine, and its receptor with disease activity in systemic lupus erythematosus in North Indian population. Rheumatol Int 33:2819–2826CrossRef

31.

Atzeni F, Boiardi L, Casali B et al (2012) CC chemokine receptor 5 polymorphism in Italian patients with Behcet’s disease. Rheumatology (Oxford) 51:2141–2145

32.

Yang X, Ahmad T, Gogus F et al (2004) Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet’s disease. Eur J Immunogenet 31:11–14PubMedCrossRef

33.

Jones KL, Maguire JJ, Davenport AP (2011) Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol 162:1453–1469PubMedCentralPubMedCrossRef

34.

Lee YH, Rho YH, Choi SJ et al (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27:827–833PubMedCrossRef

35.

Newburger JW, Fulton DR (2004) Kawasaki disease. Curr Opin Pediatr 16:508–514PubMedCrossRef

36.

Turner JE, Paust HJ, Steinmetz OM et al (2008) CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 181:6546–6556PubMedCrossRef

37.

Paxton WA, Kang S (1998) Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol 10:187–194PubMedCrossRef

38.

Prahalad S (2006) Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 7:264–268PubMedCentralPubMedCrossRef

Titel: Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren’s syndrome
Meta-analysis of possible associations
verfasst von: Y.H. Lee, MD, PhD
J.-H. Kim
G.G. Song
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 9/2014
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-014-1356-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Diagnose und Therapiestandard der Gicht in Österreich

Vaskulitis

Rituximab

Endoprothetische Versorgung des oberen Sprunggelenks

Mitteilungen